Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 37Neoplasms 30Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Rectal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Glioma 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Skin Neoplasms 1

Interventions

trametinib 1dabrafenib 1Vincristine 1Irinotecan 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroma × trametinib × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡